Eurofins Discovery Services Luxembourg Holding exceeds 50% stake in Cerep
(excluding shares being purchased in the public tender offer)
LUXEMBOURG -- February 12, 2013
Eurofins Discovery Services Luxembourg Holding (EDSL), a wholly-owned
subsidiary of Eurofins Scientific (EUFI.PA)(Paris:ERF), announces that it has
acquired over 50% of the share capital of Cerep S.A., apart from the shares
that are currently being purchased through the public tender offer which
commenced on the 24^th of January, 2013.
The result of the public tender offer, which expires on the 27^th of February,
2013, will determine how much of the share capital of Cerep S.A. EDSL has
acquired. Furthermore, the Autorité des Marchés Financiers (AMF) may decide to
extend the tender offer period for another 10 trading days commencing on the
11^th of March, 2013 to allow additional Cerep shareholders to avail of the
offer. Therefore, final ownership level will likely be determined after the
result of the extended tender offer, expected to be announced by the AMF by
the 28^th of March, 2013.
The shares already acquired by EDSL representing over 50% of the total share
capital of Cerep S.A. had been acquired through private placements and from
the open market, separate from the public tender offer. As previously
communicated, EDSL launched the tender offer, which was supported by the Board
of Directors of Cerep S.A, at a price of EUR 2 per share^1.
^1 Eurofins announcement dated 23 January 2013
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific is the world leader in food and pharmaceutical products
testing. It is also number one in the world in the field of environmental
laboratory services and one of the global market leaders in agroscience,
genomics, discovery pharmacology and central laboratory services.
With over 13,000 staff in more than 170 laboratories across 34 countries,
Eurofins offers a portfolio of over 100,000 reliable analytical methods for
evaluating the safety, identity, composition, authenticity, origin and purity
of biological substances and products. The Group provides its customers with
high-quality services, accurate results in time and expert advice by its
highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding
both its technology portfolio and its geographic reach. Through R&D and
acquisitions, the Group draws on the latest developments in the field of
biotechnology and analytical chemistry to offer its clients unique analytical
solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in
its industry, Eurofins is ideally positioned to support its clients’
increasingly stringent quality and safety standards and the expanding demands
of regulatory authorities around the world.
The shares of Eurofins Scientific are listed on the NYSE Euronext Paris Stock
Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
This press release contains forward-looking statements and estimates that
involve risks and uncertainties. The forward-looking statements and estimates
contained herein represent the judgement of Eurofins Scientific’ management as
of the date of this release. These forward-looking statements are not
guarantees for future performance, and the forward-looking events discussed in
this release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and estimates.
All statements and estimates are made based on the data available to the
Company as of the date of publication, but no guarantee can be made as to
Eurofins Investor Relations
Phone: +32-2-766 1620
For more information, please visit www.eurofins.com
Press spacebar to pause and continue. Press esc to stop.